Latest Deals

Thermo Fisher’s acqusition of Solventum will strenghtnen its capabilities in bioprocessing. Credit: JHVEPhoto / Shutterstock

Thermo Fisher Scientific is acquiring Solventum’s purification & filtration business unit in a cash deal worth around $4.1bn. Thermo Fisher expects the acquisition, which will see Solventum’s unit folded into its life sciences solutions segment once complete, to prove “highly complementary” to its bioproduction business. The deal also aims to broaden the company’s capabilities in developing and manufacturing biologics across upstream and downstream workflows. 

Boston Scientific is acquiring SoniVie, the developer of the catheter-based Tivus intravascular ultrasound system. With a current equity stake of nearly 10% in SoniVie, Boston Scientific’s transaction includes an upfront payment of approximately $360m for the remaining 90% and up to $180m upon reaching a regulatory milestone. 

Pulnovo Medical has closed a Series C financing round, securing around $100m for progressing the company’s worldwide trials, global business expansion, and strategic initiatives. Qiming Venture Partners and current Pulnovo shareholder Lilly Asia Ventures jointly led the financing round. 

UK-based OrganOx has received $142m in primary and secondary equity financing to propel the growth of its metra platform technology in the global organ technology market. New investor HealthQuest Capital led the oversubscribed financing round, with participation from current investors of the company, Lauxera Capital Partners and BGF.